Continuing education (CE) is no longer available for the 2024 STI Prevention Conference as of October 21, 2024. CE was available for plenaries, debates, clinical case series, and symposia. There were no fees for CE activities. Sessions with CE available were noted on the conference program.
OBJECTIVES
Participants should be able to:
- Discuss at least two examples of strategies that can enhance STI prevention and control efforts.
- Discuss at least two examples of STI epidemiological trends for the sexually transmitted infections covered.
- Describe how at least two factors within the health services system can affect STI prevention and treatment services.
- Describe at least two social and behavioral aspects of STI prevention.
5. List two ways to improve interprofessional collaboration in scientific research to enhance STI prevention and control.
ACCREDITATION STATEMENTS:
In support of improving patient care, this activity has been planned and implemented by Centers for Disease Control and Prevention and American Sexual Health Association (ASHA), the American Sexually Transmitted Diseases Association (ASTDA) and the National Coalition of STD Directors (NCSD). The Centers for Disease Control and Prevention is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
CME: The Centers for Disease Control and Prevention designates this live activity for a maximum of 14.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
CNE: The Centers for Disease Control and Prevention designates this activity for 14.5 nursing contact hours.
CEU: The Centers for Disease Control and Prevention is authorized by IACET to offer 1.3 CEU’s for this program.
CECH: Sponsored by the Centers for Disease Control and Prevention, a designated provider of continuing education contact hours (CECH) in health education by the National Commission for Health Education Credentialing, Inc. This program is designated for Certified Health Education Specialists (CHES®) and/or Master Certified Health Education Specialists (MCHES®) to receive up to 16 total Category I continuing education contact hours. Maximum advanced level continuing education contact hours available are 0. Continuing Competency credits available are 0. CDC provider number 98614.
For Certified Public Health Professionals (CPH)
The Centers for Disease Control and Prevention is a pre-approved provider of Certified in Public Health (CPH) recertification credits and is authorized to offer 19 CPH recertification credits for this program.
DISCLOSURE: In compliance with continuing education requirements, all planners and presenters must disclose all financial relationships, in any amount, with ineligible companies during the previous 24 months as well as any use of unlabeled product(s) or products under investigational use.
CDC, our planners, and presenters/moderators wish to disclose they have no financial relationship(s) with ineligible companies with the exception of:
Ms. Barclay and she wishes to disclose she is a recipient of Grants made to ASHA for education projects from Merck and Hologic and was a recipient of Grants made to ASHA for education projects from Roche;
Dr. Keosha Bond and she wishes to disclose she is a principal investigator with Gilead;
Dr. Cannon and he wishes to disclose he receives royalties from UpToDate and was a consultant for Roche Diagnostics;
Dr. Cohen and she wishes to disclose she is provided funding for a study of diagnostic test from Roche; and that Mayne pharma donated meds to the DoxyPEP Study; and Hologic and Cepheid donated test kits for the study;
Dr. Dombrowski and she wishes to disclose that Hologic and Mayne Pharmaceuticals donated research supplies;
Dr. Giacani and he wishes to disclose that Roche, Convergent DX, Eurofins-Diatherix, Certest Biotec and Progenika-Grifols purchased Treponema pallidum cells from his laboratory; and Progenika-Grifols and Cerus, purchased in vitro services and vivo/vitro laboratory services;
Dr. Hamill and he wishes to disclose he receives speaker fees and donation of research kits from Chembio; Cepheid and Roche Diagnostics donate research kits; receives consultancy fees from GSK, and receives royalties from UpToDate and BMJ Best Practice;
Dr. Hazra and she wishes to disclose she has unrestricted research and is on the advisory board with Gilead Sciences; and is on the advisory board of ViiV Healthcare;
Jen Hecht and she wishes to disclose she receives funds for her organization from Gilead; and received funds for her organization from OraSure.
Dr. Hsu and she wishes to disclose she was a member and on a medical advisory board with Talis Biomedical Corporation;
Dr. Kelley and she wishes to disclose she receives a research grant to institution from Viiv and Gilead Sciences; and received a research grant to institution from Moderna, Novavax, Humanigen;
Dr. Khosropour and she wishes to disclose that Hologic, Inc donated research supplies and that she received a grant for research project from Gilead Sciences;
Dr. Logie and she wishes to disclose she received a “Positive Action for Adolescents Grant” for an HIV prevention study with refugee youth in Bidi Bidi refugee camp, Uganda from ViiV Healthcare UK;
Dr. Manabe and she wishes to disclose she receives research grant to her institution from Hologic, Chembio, Cepheid and Roche;
Dr. McNeil and she wishes to disclose she conducts clinical trial with BD; and she conducted clinical trial with BARDA/GSK and Cepheid; and she received grants from Gilead and Hologic; and she was on the advisory board with Talis Biomedical;
Dr. Nelson and he wishes to disclose he is on the Advancing Health Equity Advisory Board with ViiV Healthcare; and he was Subject Matter Expert with Gilead Sciences;
Dr. Ramchandani and she wishes to disclose she was a study clinician at Nabriva with money paid to the institution;
Dr. Reno and she wishes to disclose she received a grant to Washington University from Hologic, Inc.;
Dr. Sanchez and he wishes to disclose that ViiV Healthcare funded Emory University research studies on HIV PrEP preferences, including partial funding for the study that will be discussed; he is the study PI;
Dr. Tuddenham and she wishes to disclose she receives royalties from UpToDate; and she participates in research supported by in-kind donation of STI test kits to institution from Hologic;
Dr. Wendel and she wishes to disclose that Hologic supported the MyGenius Project with financial support to her institution, and she was the PI of the project;
Gregory Zane and he wishes to disclose he has a summer internship (June-August 2024) with Merck and Co., Inc.
All relevant financial relationships listed for these individuals have been mitigated.
Presentations will not include any discussion of the unlabeled use of a product or a product under investigational use with the exception of:
Dr. Cohen’s discussion of Doxycycline. She will be discussing Doxycycline for STI PEP is an off-label use.
Dr. Hamill’s discussion of Doxycycline. He will be discussing the use of doxycycline as prophylaxis against bacterial STIs.
Jen Hech’s discussion of lab-developed tests for self-collection of STIs. She will reference the use of lab-developed tests for self-collection of STIs. These tests have been validated by the labs, but FDA has suggested they may need to go through additional approval processes.
Dr. Kelley’s discussion of Doxycycline. She will be discussing that Doxycycline does not carry label for STI-PEP.
Dr. Mermin’s discussion of Doxycycline. He will be discussing Doxycycline post-exposure prophylaxis—it is currently an off-label use, although it is recommended in new CDC guidelines.
Dr. Sherbuk’s discussion on tecovirimat. She will be discussing a case presentation describing the management of a patient with Mpox infection. As part of the case description, the use of tecovirimat for Mpox infection in this patient will be described. Tecovirimat is under investigational use for Mpox infection.
Dr. Wendel’s discussion on molecular testing for Mycoplasma antibiotic resistance. She will describe use of molecular testing for Mycoplasma antibiotic resistance. This testing is not approved in the U.S.
Dr. Zucker’s discussion on tecovirimat. He will be discussing Tecovirimat for Mpox is used via an EA-IND or STOMP study (with an IND).
CDC did not accept financial or in-kind support from ineligible companies for this continuing education activity.